Subscribe

Glossary

Uveitis

Inflammation inside the eye. In rheumatic disease it usually hits the front of the eye, comes on fast, and needs seeing the same day rather than at your next appointment.

This is the one eye problem worth knowing the warning signs for, and they're easy enough to remember. It comes on over hours rather than days. How fast it gets looked at changes what happens next, which is why this page says the urgent part more than once.

Quick answerUveitis is inflammation inside the eye, and in rheumatic disease it usually hits the front of the eye and starts fast. One review reports it in 33 percent of people with ankylosing spondylitis. Sudden eye pain, redness, blurred vision, or new trouble with bright light needs looking at the same day rather than at your next appointment.
How often it happens depends on which illness you have and on how long you've had it. One review puts it at 33 percent in ankylosing spondylitis, 25 percent in reactive arthritis, 6 to 9 percent in psoriatic arthritis, and 2 to 5 percent in bowel-related disease. One study tracked a single group over time, and at diagnosis 11.5 percent had had an attack while twenty years later it was 39.3 percent. So a long quiet stretch isn't a guarantee, and knowing the warning signs is the useful response rather than watching for them.

What it is

Uveitis means inflammation inside the eye, and the word comes from the uvea, which is the middle layer of the eyeball. Doctors sort it by where in the eye it is. Anterior uveitis affects the front, posterior affects the back, intermediate falls between the two, and panuveitis means the whole thing is involved.

That distinction counts, because the two ends of the eye behave differently. In rheumatic disease most attacks are anterior and those usually do well. A minority reach the back of the eye, and one review notes those are more often complicated by swelling at the center of vision and by sight loss. That difference is the whole reason for the urgency below.

Why it's a same-day problem

You can't tell from the outside whether an attack has reached the back of the eye, and neither can anybody else. It takes looking in with the right equipment. That's the whole reason for the urgency, because some attacks do well and some threaten sight, and from your point of view the two start out looking alike.

So sudden eye pain, redness, blurred vision, or new trouble with bright light is a same-day problem. It doesn't wait for next week, and it doesn't wait for your next rheumatology appointment. That's the one sentence on this page worth remembering, and being told it once is usually enough to make it stick.

Which drugs cut the attacks

They don't all behave alike, and the difference between them is one of the more useful things on this page. Plenty of people assume a drug that helps the joints must help the eyes. That study compared how many attacks people had before starting treatment with how many they had after.

Among 27 people on tumor necrosis factor antibodies, attacks fell from 1.83 per person to 0.41, at P equals 0.002. Among 19 people on etanercept they didn't fall, going from 0.44 to 0.79 instead. Those are small groups, and the review that follows reaches that conclusion from a much wider base.

That review names infliximab, adalimumab, and certolizumab as effective at reducing how often uveitis happens, and it names etanercept as not. It adds that one interleukin 17A blocker, secukinumab, hasn't been shown effective in uveitis. So the family a drug belongs to doesn't settle the question, and neither does how well it works on your joints.

A newer drug in that family points the other way, and its figures are worth having. Two trials pooled their double-blind periods, and uveitis occurred in 2 of 349 people on bimekizumab, which is 0.6 percent, against 11 of 237 on placebo, which is 4.6 percent. The nominal P value was 0.001, and across a wider pool of 848 patients the rate stayed low.

Those numbers are worth raising with your own team, and that goes double if you've had attacks before. They aren't figures to act on alone. What they're good for is turning a vague worry about your eyes into a specific question somebody can answer.

When uveitis comes first

Sometimes the eye trouble arrives before anybody has mentioned arthritis, and that turns out to be worth knowing. It changes a good deal about what happens afterwards. One registry held 2367 patients with spondyloarthritis, of whom 379 had this kind of uveitis.

Among those 379, the eye trouble came first or alongside for 59 people and afterwards for 229. The ones whose eyes came first did better on every measure the registry looked at. They had better function, at an odds ratio of 0.85 from 0.73 to 0.99, and less structural damage, at 0.88 from 0.79 to 0.99. They were also diagnosed faster, at 0.90 from 0.84 to 0.96.

That last figure probably explains a good deal of the rest. An eye attack sends somebody to a specialist quickly, and the arthritis then gets found while there's still less of it to find. It's an argument for speed rather than an argument about the eye itself.

Common misconceptions.

Myth. Sore red eyes can wait for my next appointment.

Reality. Not these ones, because uveitis in rheumatic disease usually comes on over hours rather than days. Sudden eye pain, redness, blurred vision, or new trouble with bright light needs looking at the same day. Most attacks hit the front of the eye and do well, while a minority hit the back, and those are more often complicated by swelling at the center of vision and by sight loss.

Myth. It's a rare complication.

Reality. It's the most common thing that happens outside the joints in this group of illnesses. One review reports it in 33 percent of people with ankylosing spondylitis, and one Moroccan study of 136 people with spondyloarthritis found it the most frequent feature outside the joints, at 18.4 percent. So this isn't a rarity, and it's the main one to know about.

Myth. If I haven't had it by now, I won't.

Reality. The risk keeps accumulating, which is the opposite of reassuring and still worth knowing. One study followed 301 people with spondyloarthritis and measured how many had ever had an attack, and at the point of diagnosis it was 11.5 percent. Twenty years later it was 39.3 percent, so a long quiet stretch means you've been lucky so far rather than that you're safe.

Myth. Any arthritis drug will protect my eyes.

Reality. They don't all behave alike here, and one study measured the difference. It compared attacks before and after treatment, and people on tumor necrosis factor antibodies had fewer, falling from 1.83 to 0.41 per person, at P equals 0.002. People on etanercept did not, going from 0.44 to 0.79, and one review lists three antibody drugs as effective at cutting attacks while naming etanercept as not.

Myth. Uveitis means I must have a rheumatic disease.

Reality. Often it means nothing of the kind, and the numbers on that are striking. One clinic worked up 912 people referred with uveitis, and it stayed unexplained in 46.9 percent while a whole-body disease explained 37.3 percent. The most common of those was sarcoidosis at 17.1 percent, with HLA-B27-related disease next at 12.5 percent, and the authors note about 60 causes have been described.

Related terms.

References.

  1. Sharma SM; Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31:846-862. 10.1016/j.berh.2018.08.002Review of uveitis in the spondyloarthropathies
  2. Frantz C; Portier A; Etcheto A et al. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clin Exp Rheumatol. 2019;37:26-31. PMID 30620268Cross-sectional single-centre observational study
  3. Brown MA; Rudwaleit M; van Gaalen FA et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024;83:1722-1730. 10.1136/ard-2024-225933Pooled analysis of uveitis incidence across phase 2b and phase 3 randomised controlled trials of bimekizumab in axial spondyloarthritis
  4. Bertrand PJ; Jamilloux Y; Ecochard R et al. Uveitis: Autoimmunity… and beyond. Autoimmun Rev. 2019;18:102351. 10.1016/j.autrev.2019.102351Review of the records of 912 consecutive patients referred to a hospital internal medicine department for diagnostic work-up of uveitis
  5. Gómez-García I; Ladehesa-Pineda ML; Puche-Larrubia MÁ et al. Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry. Joint Bone Spine. 2021;88:105136. 10.1016/j.jbspin.2021.105136Cross-sectional analysis of the Spanish national spondyloarthritis registry REGISPONSER
  6. Bubova K; Hasikova L; Mintalova K et al. The Prevalence of MRI-Defined Sacroiliitis and Classification of Spondyloarthritis in Patients with Acute Anterior Uveitis: A Longitudinal Single-Centre Cohort Study. Diagnostics (Basel). 2022;12. 10.3390/diagnostics12010161Longitudinal single-centre cohort
  7. Essouiri J; Abourazzak FE; Kona I et al. Profile of Patients with Spondyloarthritis in Morocco. Curr Rheumatol Rev. 2018;14:258-263. 10.2174/1573397113666170406125338Retrospective observational study in one Moroccan rheumatology department analysing the records of 136 patients diagnosed with spondyloarthritis between January 2009 and June 2014
  8. Hong C; Kwan YH; Leung YY et al. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore. Int J Rheum Dis. 2019;22:1506-1511. 10.1111/1756-185X.13603Comparative study of 262 patients with axial spondyloarthritis in a Singapore registry

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.